Pardes Biosciences, Inc. financial data

Industry
Pharmaceutical Preparations
Location
2173 Salk Avenue, Suite 250, Pmb#052, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
FS Development Corp. II (to 12/23/2021)
Latest financial report
10-Q - Q2 2023 - Aug 4, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.63K % -32.8%
Debt-to-equity 6.52 % +18.3%
Return On Equity -43.4 % -1.1%
Return On Assets -40.7 % -31.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62M shares -0.5%
Common Stock, Shares, Outstanding 60.4M shares +4.17%
Entity Public Float 115M USD -43%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.2M shares +4.37%
Weighted Average Number of Shares Outstanding, Diluted 60.2M shares +4.37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 56.7M USD +9.1%
General and Administrative Expense 26.2M USD +12.8%
Nonoperating Income (Expense) 298K USD +7350%
Net Income (Loss) Attributable to Parent -76.1M USD -1.6%
Earnings Per Share, Basic -1.28 USD/shares +62.5%
Earnings Per Share, Diluted -1.28 USD/shares +62.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 100M USD -56.1%
Cash, Cash Equivalents, and Short-term Investments 153M USD
Assets, Current 157M USD -32.7%
Other Assets, Noncurrent 0 USD
Assets 157M USD -32.7%
Accounts Payable, Current 14K USD -99.2%
Employee-related Liabilities, Current 674K USD -68.4%
Accrued Liabilities, Current 1.91M USD -80%
Liabilities, Current 1.93M USD -82.8%
Liabilities 1.93M USD -82.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9K USD
Retained Earnings (Accumulated Deficit) -177M USD -75.7%
Stockholders' Equity Attributable to Parent 155M USD -30.2%
Liabilities and Equity 157M USD -32.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.5M USD -30.3%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 61.7M shares -1.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.3M USD -77.9%
Deferred Tax Assets, Valuation Allowance 30.8M USD +228%
Deferred Tax Assets, Gross 30.8M USD +228%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -76.1M USD +61.1%
Deferred Tax Assets, Operating Loss Carryforwards 14M USD +61.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.27M USD +166%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.88M USD +40.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%